The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis

OBJECTIVE: Prevention of steroidal osteoporosis is an important issue. There is no clear consensus on the impact of anti-RANKL antibody (denosumab) on BMD in patients with glucocorticoid-induced osteoporosis (GIO). In this study, we aimed to evaluate the impact of denosumab on BMD loss in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Yuta, Morita, Takayoshi, Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197806/
https://www.ncbi.nlm.nih.gov/pubmed/32373775
http://dx.doi.org/10.1093/rap/rkaa008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197806/
https://www.ncbi.nlm.nih.gov/pubmed/32373775
http://dx.doi.org/10.1093/rap/rkaa008

Ejemplares similares